Cardiovascular thromboembolic events associated with febuxostat: Investigation of cases from the FDA adverse event reporting system database

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 6, 2013, Pages 562-566

  Gandhi, Pranav K ^a   Gentry, William M ^a   Bottorff, Michael B ^a  

^a South College School of Pharmacy   (United States)

Author keywords

Adverse event reporting system database; Cardiovascular thromboembolic events; Febuxostat; Food and Drug Administration; Gout

Indexed keywords

FEBUXOSTAT;

ACUTE HEART INFARCTION; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; BRAIN EMBOLISM; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY THROMBOSIS; DATA MINING; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GOUT; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFORMATION PROCESSING; JUGULAR VEIN THROMBOSIS; KIDNEY VEIN THROMBOSIS; LUNG EMBOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CHILD; DATA MINING; FEMALE; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; THIAZOLES; THROMBOEMBOLISM; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84881239406     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.11.002     Document Type: Article

References (17)

1. Uloric prescribing information. Dearfield IL: Takeda Pharmaceuticals North America, Inc.; 2009.
2. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353(23):2450-2461.
3. Schumacher H.R., Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum 2008, 59(11):1540-1548.
4. Wortmann RL, Becker MA, Schumacher HR. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. Abstract presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting. Washington, DC, USA, 10-15 November 2006. [Abstract no. 1592].
5. Becker M, Schumacher H, MacDonald PA. Urate-lowering therapy in subjects with gout: interim results from the febuxostat comparative extension long-term study (EXCEL). Abstract presented at the Annual European Congress of Rheumatology (EULAR). Barcelona, Spain, 13-16 June 2007. [Abstract no. THU0339].
6. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Brit Med J 1994;308(6921):81-106.
7. Edwards N.L. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology 2009, 48(Suppl 2):ii15-ii19. 10.1093/rheumatology/kep088.
8. Piccinni C., Marchesini G., Motola G., Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011, 34(6):1369-1371.
9. van Puijenbroek E.P., Bate A., Leufkens H.G.M., Lidquist M., Orre R., Egberts A.C.G. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002, 11(1):3-10.
10. Noren G.N., Bate A., Orre R., Edwards I.R. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med 2006, 25(21):3740-3757.
11. Ratcliffe S., Younus M., Hauben M., Reich L. Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spontaneous reporting of cardiomyopathy. J Psychopharmacol 2010, 24:503-511.
12. Krishnan E., Svendsen K., Neaton J.D., Grandits G., Kuller L.H. MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008, 168(10):1104-1110.
13. Gagliardi A.C., Miname M.H., Santos R.D. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 2009, 202(1):11-17.
14. Puig J.G., Martinez M.A. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008, 20(2):187-191.
15. Bate A., Lindquist M., Edwards I.R., Olsson S., Orre R., Lansner A., et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998, 54(4):315-321.
16. Hauben M., Reich L., Gerrits C.M. Reports of hyperkalemia after publication of RALES-a pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006, 15(11):775-783.
17. Kelly W.N., Arellano F.M., Barnes J., Bergman U., Edwards R.I., Fernandez A.M., et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007, 30(5):367-373.